ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2026)

ARS Pharmaceuticals has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $978000.0 in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 26.96% year-over-year to $978000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $978000.0 (down 26.96% YoY) and the FY2025 annual result came in at $1.1 million, down 26.24% from the prior year.
• Non-Current Deffered Revenue declined to $978000.0 in Q1 2026 per SPRY's latest filing, from $1.1 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.9 million in Q4 2022 and troughed at $978000.0 in Q1 2026.
• A 4-year average of $1.5 million and a median of $1.3 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deffered Revenue declined 4.74% in 2022, then declined 26.96% in 2026.
• Over 4 years, Non-Current Deffered Revenue stood at $2.9 million in 2022, then sank by 46.32% to $1.5 million in 2024, then dropped by 26.24% to $1.1 million in 2025, then dropped by 13.45% to $978000.0 in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $978000.0, $1.1 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.